📰 Eric Zi News
Page 3 - Eric Zi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Zi. Real-time updates on events, politics, business and more.
January 26, 2022
HANGZHOU, China, Jan. 25, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural he...
January 26, 2022
/PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its...
January 26, 2022
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its
December 9, 2021
/CNW/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its...
December 8, 2021
/PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its...
December 8, 2021
/PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its...
December 8, 2021
Venus Medtech ( Hangzhou ) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve),
December 8, 2021
HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its
December 8, 2021
JERUSALEM, Dec. 8 (Xinhua) -- Chinese heart disease treatment company Venus Medtech has acquired the Israeli company Cardiovalve for 300 million U.S. dollars, b
July 28, 2021
Share this article Share this article HANGZHOU, China, July 27, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech (Hangzhou) Inc. ("Venus Medtech") (stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions in China, and its controlling subsidiary Renaly Ltd., announced that Professor Martin B. Leon, MD, a pioneer in the field of interventional cardiovascular devices, has been appointed as the Global Principal Investigator (PI) for its new-gene...